NASDAQ · ACET
Healthcare · Biotechnology
$3.17
Down-$0.11 (-3.47%)
Updated Nov 4, 2026, 5:29 PM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ACET
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
ACET closed at $3.17 after 21 trading sessions, down 49.28% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $3.20 | $3.34 | $3.13 | $3.17 | 176.38K |
| Nov 2, 2026 | $3.42 | $3.465 | $3.18 | $3.20 | 250.31K |
| Oct 30, 2026 | $3.68 | $3.74 | $3.32 | $3.42 | 242.49K |
| Oct 29, 2026 | $3.83 | $3.86 | $3.56 | $3.58 | 176.21K |
| Oct 28, 2026 | $3.80 | $3.86 | $3.71 | $3.81 | 178.82K |
| Oct 27, 2026 | $3.94 | $3.97 | $3.77 | $3.81 | 178.17K |
| Oct 26, 2026 | $4.00 | $4.055 | $3.81 | $3.94 | 162.81K |
| Oct 23, 2026 | $4.22 | $4.29 | $3.96 | $3.99 | 162.97K |
| Oct 22, 2026 | $4.50 | $4.72 | $4.21 | $4.28 | 157.16K |
| Oct 21, 2026 | $4.52 | $4.7356 | $4.44 | $4.49 | 182K |
| Oct 20, 2026 | $4.53 | $4.715 | $4.49 | $4.52 | 126.53K |
| Oct 19, 2026 | $4.57 | $4.745 | $4.39 | $4.53 | 230.32K |
| Oct 16, 2026 | $5.14 | $5.14 | $4.57 | $4.57 | 188.79K |
| Oct 15, 2026 | $4.90 | $5.17 | $4.88 | $5.14 | 155.1K |
| Oct 14, 2026 | $5.10 | $5.27 | $4.8001 | $4.89 | 357.87K |
| Oct 13, 2026 | $5.53 | $5.53 | $5.10 | $5.11 | 326.9K |
| Oct 12, 2026 | $5.55 | $5.84 | $5.17 | $5.53 | 145.88K |
| Oct 9, 2026 | $5.72 | $6.05 | $5.605 | $5.61 | 189.83K |
| Oct 8, 2026 | $6.16 | $6.17 | $5.5501 | $5.74 | 487.86K |
| Oct 7, 2026 | $6.21 | $6.44 | $6.12 | $6.18 | 214.3K |
| Oct 6, 2026 | $6.52 | $6.55 | $6.21 | $6.25 | 135.72K |
The latest Smart Investors Daily articles mentioning ACET.
Company
Market Activity
Research & News
ACET research
Company profile and research snapshot.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 29, 2026 | Wedbush | Outperform | — |
| Sep 28, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 18, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 6, 2026 | Guggenheim | Buy | — |
| Mar 23, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 22, 2026
REDWOOD CITY, Calif., October 22, 2026--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced that company management will participate in two upcoming investor conferences in November.
Yahoo · Oct 3, 2026
Adicet Bio (NASDAQ:ACET) reported positive clinical data for prula-cel, its investigational allogeneic gamma delta CAR-T cell therapy, in patients with systemic lupus erythematosus, or SLE, including patients with lupus nephritis. The company said that, among evaluable lupus nephritis patients, 50%
SeekingAlpha · Sep 30, 2026
2026-09-30. The following slide deck was published by Adicet Bio, Inc.
Benzinga · Sep 29, 2026
Wedbush analyst Robert Driscoll maintains Adicet Bio (NASDAQ:ACET) with a Outperform and raises the price target from $25 to $28.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ACET.
No results
No recent SID articles mention ACET.
